Aravis Ventures
VC Fund
Zürich, Switzerland
Aravis Ventures is a VC fund in Zürich focused on Biotechnology and Health Care. Aravis is the first independent Swiss on-shore private equity house, an established investor in the renewable energy and life science spaces. We are a "hands-on" investor taking leading positions and understanding the balance between finance, commercial assets and people. With this distinct and crafted approach, we are serving over 30leading investors including corporates, pension funds, government funds, insurance companies and family offices. Currently actively managing more than a quarter of a billion Swiss francs, we have a cumulative history of investments in over 100 companies. These have resulted in several noticeable exits including the divestment of several renewable energy companies and a number of life science reverse take-overs, listings and trade sales. Our many years of experience in the Swiss fund industry have enabled us to establish a platform with a comprehensive offering of investment, accounting, regulatory and reporting expertise. Located in Zurich, Aravis was founded in 2001.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 32%
Last updated:
For AI agents: llms.txt
Industries Aravis Ventures invests in
Stages Aravis Ventures invests in
Countries Aravis Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $4.4M–$80M
- Series B
- $6.8M–$33M
Investment Focus
Industry
- Biotechnology 9 (47%)
- Health Care 5 (26%)
- Therapeutics 3 (16%)
- Medical 2 (11%)
- Pharmaceutical 2 (11%)
Stage
- Series A 8 (42%)
- Series B 4 (21%)
- Series C 1 (5%)
- Series E 1 (5%)
- Post-IPO Equity 1 (5%)
Country
- Switzerland 3 (16%)
- United States 3 (16%)
- Denmark 1 (5%)
- Singapore 1 (5%)
- The Netherlands 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jean-Philippe Tripet
Founder and Chairman
|
Founder and Chairman | Total investments: 3 | Find email | |
Andreas Jacobs
Managing Partner & CFO
|
Managing Partner & CFO | Total investments: 0 | Find email | |
Kadri Vunder
Investment Manager
|
Investment Manager | Total investments: 0 | Find email | |
Marc Krattinger
Partner
|
Partner | Total investments: 0 | Find email | |
Margaretha Bruelisauer
Accountant
|
Accountant | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Hedera-22
|
Hedera-22 expanded its scope to include the identification of natural products through the use of in-house bio-informatic prediction technologies. | $2.2M / Venture - Series Unknown / Aug 14, 2024 | |
Bird Rock Bio
|
Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicatedin inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators. | $15M / Series B / Mar 27, 2014 | |
Synaffix BV
|
Synaffix BV is a clinical-stage, Netherlands-based biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability compared to all 3 major clinical-stage ADC technologies. We have a 'one-stop' technology offering (including 4 different ADC payloads) thatenables the development of proprietary ADCs from any antibody and our patent portfolio provides patent protection of resulting Products through at least 2035.Our business model is technology out-licensing and we regularly engage in research collaborations with other companies that are interested in developing highly competitive ADC products for their own pipelines.Disclosed partnerships to date include those with ADC Therapeutics and Mersana Therapeutics | Series A / Feb 18, 2014 | |
Bellerophon Therapeutics
|
Bellerophon Therapeutics LLC is a clinical stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitricoxide delivery device, INOpulse®, and are in Phase 2 clinical trials – one for the treatment of PAH and a second for the treatment of PH-COPD. The company's third product candidate, bioabsorbable cardiac matrix (BCM), is an injectable device currently undergoing a feasibility clinical trial, which is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in U.S. drug development, for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (heart attack). | $80M / Series A / Dec 26, 2013 | |
Telormedix
|
Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. | $6.8M / Series B / Dec 02, 2013 | |
|
Telormedix
|
Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. | $7M / Series B / Jan 25, 2012 | |
MerLion Pharma
|
MerLion Pharmaceuticals.drug discovery and development company, engages in the research and development of natural products. It operates through two business units, MerLion Research and MerLion Development. The MerLion Research unit is a contract services business, which provides access to natural product collections by offering sample/extractsupply services, extract profiling and standardization, assay development, throughput screening, compound purification and structural identification, biocatalyst isolation, and strain improvement. The MerLion Development unit is progressing finafloxacin, a differentiated antibacterial candidate through phase II clinical trials, which is targeted initially for the eradication of Helicobacter pylori and treatment of urinary tract infections. It also provides portfolio of earlier-stage, preclinical antibacterial, and oncology programmes. The company serves pharmaceutical, industrial biotechnology, agro science, food and flavorings, cosmetics, and personal healthcare companies. MerLion Pharmaceuticals Pte. Ltd. was founded in 2002 and is based in Singapore, Singapore with clinical development operations in Berlin, Germany. | $7M / Series C / Oct 11, 2010 | |
Evolva
|
Evolva is a biotech company that develops and commercializes ready-to-formulate and nature-based ingredients. Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small-molecule drugs and other compounds. In particular, their platform allows the creation of chemistriesthat recapitulate the themes found in natural products, but without the disadvantages of those approaches.The company is headquartered in Reinach, Switzerland. | $27.5M / Post-IPO Equity / Dec 11, 2009 | |
|
Evolva
|
Evolva is a biotech company that develops and commercializes ready-to-formulate and nature-based ingredients. Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small-molecule drugs and other compounds. In particular, their platform allows the creation of chemistriesthat recapitulate the themes found in natural products, but without the disadvantages of those approaches.The company is headquartered in Reinach, Switzerland. | $18.7M / Series B / Dec 11, 2009 | |
|
Evolva
|
Evolva is a biotech company that develops and commercializes ready-to-formulate and nature-based ingredients. Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small-molecule drugs and other compounds. In particular, their platform allows the creation of chemistriesthat recapitulate the themes found in natural products, but without the disadvantages of those approaches.The company is headquartered in Reinach, Switzerland. | $32.6M / Series B / Oct 22, 2009 | |
| See all 19 investments → | |||
Co-Investors
BioMedPartners
4 deals together
Novartis Venture Fund
4 deals together
M Ventures
3 deals together
ProQuest Investments
3 deals together
VINCI CAPITAL
3 deals together
5AM Ventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Aravis Ventures invest in?
Aravis Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 19 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Aravis Ventures's check size?
Aravis Ventures typically joins rounds of $4.4M–$80M at Series A and $6.8M–$33M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Aravis Ventures participates in.
How do I contact Aravis Ventures?
Public channels for Aravis Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Aravis Ventures?
The team at Aravis Ventures includes Jean-Philippe Tripet (Founder and Chairman), Andreas Jacobs (Managing Partner & CFO) and Kadri Vunder (Investment Manager), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
